Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy versus letrozole + palbociclib in low/intermediate-risk luminal breast cancer
2014-002560-33Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jan 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palbociclib, letrozole, fluorouracil, epirubicin, cyclophosphamide and 1 more in breast cancer, hormone receptor-positive/HER2-negative breast cancer and luminal breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Residual Cancer Burden 0-I rate. Started Jan 2015; status: completed.
02
Drugs
palbociclibletrozolefluorouracilepirubicincyclophosphamide
03
Conditions
breast cancerhormone receptor-positive/HER2-negative breast cancerluminal breast cancer
Beyond the preview
Go deeper on 2014-002560-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002560-33.